ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors

Li, Shu-hui; Li, Yi-Wen; Li, Ying-Jue; Liu, Lin-Bo; Zhang, Qun; Lu, Dan*哈尔滨医科大学
International Journal of General Medicine2023DOI: 10.2147/IJGM.S426590
5阅读
引用收藏
分享

摘要

Objective: To investigate the clinical efficacy and safety of anlotinib combined with anti-PD-1 inhibitors in the 2nd or later-line treatment of advanced solid tumors. Patients and Methods: A total of 63 patients with advanced solid tumors who had failed or could not endure the adverse reactions after receiving first-line or more systematic treatment in the Second Affiliated Hospital of Harbin Medical University from March 2019 to April 2023 were treated with anlotinib Hydrochloride capsule combined with anti-PD-1 inhibitors. The efficacy and adverse reactions were evaluated according to RECIST1.1 and NCICTC4.0 standards. Results: The percentage of overall response rate of 63 patients during the combination administration indicated that complete response was 1.6% (n=1), partial response was 23.8% (n=15), stable disease was 39.7% (n=25) and progressive disease was 34.9% (n=22), yielding objective response rate (ORR) of 25.4% and disease control rate (DCR) of 65.1%. Furthermore, the median PFS of 63 patients with advanced solid tumors was 7 months and the median OS was not reached, and the median follow-up time is 4.5 months. In subgroup analysis, there was no significant difference in PFS between first-line, second-line, third-line and above (p=0.631); there was no significant difference in PFS between PD-1 positive patients and PD-1 negative patients (p=0.094); there was no significant difference in PFS between patients who had previously used anti-PD-1 inhibitors and patients who had not used before (p=0.204). The most common adverse reactions were hypertension, hand-foot syndrome, and fatigue, with an incidence of 28.4% (18/63), 25.6% (14/ 63), and 25.6% (14/63), respectively. Most of the adverse reactions were grade 1-2, and there were no grade 4 adverse reactions. Conclusion: Anlotinib combined with anti-PD-1 inhibitors demonstrated promising efficacy and tolerable safety for patients with advanced solid tumors in the 2nd or later-line treatment.

学科与关键词

关键词
anlotinibanti-PD-1 inhibitoradvanced solid tumorsadverse reactions
相关
加载中…
  • The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Wang, Fen*; Jin, Feng; Cheng, Boran; Zhang, Yue; Zhou, Qing; Wang, ShubinJournal of Cancer Research and Clinical Oncology, 2022, 148(7): 1721-1735.被引 3
  • Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
    Shi, Jianhua; Cheng, Ying*; Wang, Qiming; Li, Kai; Wu, Lin; Han, Baohui; Chen, Gongyan; He, Jianxing; Wang, Jie; Qin, Haifeng; Li, XiaolingFrontiers of Medicine, 2022, 16(5): 766-772.被引 5
  • Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)
    Song, Bo; Hu, Hai; Zhang, Li; Ye, Su-Juan; Jin, Yong-Dong; Shang, Chang-Ling; Zhang, Jun; Sun, Hao; Zhang, Ke; Yi, Bo; Han, Yun-Wei*; Yan, Jin*Frontiers in Oncology, 2023, 13: 1238553.
查看全部 →

发表信息

论文状态
公开发表
期刊
International Journal of General Medicine
发表日期
2023
卷期
第 16 卷
页码
4485-4498
DOI
10.2147/IJGM.S426590
成果收录
SCIE

作者

  • L

    Li, Shu-hui (第一作者)

    2 · harbin med univ

  • L

    Li, Yi-Wen

    2 · harbin med univ

查看全部 6 位作者收起作者
  • L

    Li, Ying-Jue

    2 · harbin med univ

  • L

    Liu, Lin-Bo

    2 · harbin med univ

  • Z

    Zhang, Qun

    2 · harbin med univ

  • L

    Lu, Dan (通讯)

    2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417